Systemic, nasal and oral live vaccines against Pseudomonas aeruginosa: a clinical trial of immunogenicity in lower airways of human volunteers. (Q50052368)

From Wikidata

Jump to navigation Jump to search

scientific article published in November 2009

Language	Label	Description	Also known as
English	Systemic, nasal and oral live vaccines against Pseudomonas aeruginosa: a clinical trial of immunogenicity in lower airways of human volunteers.	scientific article published in November 2009

Statements

scholarly article

1 reference

Europe PubMed Central

24 February 2018

http://europepmc.org/abstract/MED/19887136

Systemic, nasal and oral live vaccines against Pseudomonas aeruginosa: a clinical trial of immunogenicity in lower airways of human volunteers. (English)

1 reference

Europe PubMed Central

24 February 2018

http://europepmc.org/abstract/MED/19887136

Pseudomonas aeruginosa

1 reference

based on heuristic

inferred from title

author name string

Dirk Bumann

1

1 reference

Europe PubMed Central

24 February 2018

http://europepmc.org/abstract/MED/19887136

Christoph Behre

2

1 reference

Europe PubMed Central

24 February 2018

http://europepmc.org/abstract/MED/19887136

Katharina Behre

3

1 reference

Europe PubMed Central

24 February 2018

http://europepmc.org/abstract/MED/19887136

Steffen Herz

4

1 reference

Europe PubMed Central

24 February 2018

http://europepmc.org/abstract/MED/19887136

Britta Gewecke

5

1 reference

Europe PubMed Central

24 February 2018

http://europepmc.org/abstract/MED/19887136

J Engelbert Gessner

6

1 reference

Europe PubMed Central

24 February 2018

http://europepmc.org/abstract/MED/19887136

Bernd Ulrich von Specht

7

1 reference

Europe PubMed Central

24 February 2018

http://europepmc.org/abstract/MED/19887136

Ulrich Baumann

8

1 reference

Europe PubMed Central

24 February 2018

http://europepmc.org/abstract/MED/19887136

language of work or name

0 references

publication date

1 November 2009

1 reference

Europe PubMed Central

24 February 2018

http://europepmc.org/abstract/MED/19887136

1 reference

Europe PubMed Central

24 February 2018

http://europepmc.org/abstract/MED/19887136

28

1 reference

Europe PubMed Central

24 February 2018

http://europepmc.org/abstract/MED/19887136

3

1 reference

Europe PubMed Central

24 February 2018

http://europepmc.org/abstract/MED/19887136

707-713

1 reference

Europe PubMed Central

24 February 2018

http://europepmc.org/abstract/MED/19887136

A double-blind randomized placebo-controlled phase III study of a Pseudomonas aeruginosa flagella vaccine in cystic fibrosis patients

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.080

7 January 2021

Vaccines and immunotherapy against Pseudomonas aeruginosa

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.080

7 January 2021

Antibody responses induced by long-term vaccination with an octovalent conjugate Pseudomonas aeruginosa vaccine in children with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.080

7 January 2021

Plasma-cell homing

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.080

7 January 2021

Mucosal immunity and vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.080

7 January 2021

Mucosal vaccination against bacterial respiratory infections

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.080

7 January 2021

Live attenuated versus inactivated influenza vaccine in infants and young children.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.080

7 January 2021

Induction of protective serum meningococcal bactericidal and diphtheria-neutralizing antibodies and mucosal immunoglobulin A in volunteers by nasal insufflations of the Neisseria meningitidis serogroup C polysaccharide-CRM197 conjugate vaccine mixed

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.080

7 January 2021

Intranasal immunisation with conjugate vaccine protects mice from systemic and respiratory tract infection with Pseudomonas aeruginosa

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.080

7 January 2021

Immunisation with non-integral OMPs promotes pulmonary clearance ofPseudomonas aeruginosa

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.080

7 January 2021

Protection against fatal Pseudomonas aeruginosa pneumonia in mice after nasal immunization with a live, attenuated aroA deletion mutant

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.080

7 January 2021

Immune response mechanisms against Pseudomonas aeruginosa associated with mucosal immunization with protein antigens in a rat model of acute lung infection.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.080

7 January 2021

Recombinant OprF-OprI as a vaccine against Pseudomonas aeruginosa infections

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.080

7 January 2021

Assessment of pulmonary antibodies with induced sputum and bronchoalveolar lavage induced by nasal vaccination against Pseudomonas aeruginosa: a clinical phase I/II study

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.080

7 January 2021

Mucosal vaccination with a recombinant OprF-I vaccine of Pseudomonas aeruginosa in healthy volunteers: comparison of a systemic vs. a mucosal booster schedule.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.080

7 January 2021

A recombinant hybrid outer membrane protein for vaccination against Pseudomonas aeruginosa

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.080

7 January 2021

Safety and immunogenicity of an intranasal Pseudomonas aeruginosa hybrid outer membrane protein F-I vaccine in human volunteers

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.080

7 January 2021

Clinical study to assess the immunogenicity and safety of a recombinant Pseudomonas aeruginosa OprF-OprI vaccine in burn patients.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.080

7 January 2021

Enhanced immunogenicity in the murine airway mucosa with an attenuated Salmonella live vaccine expressing OprF-OprI from Pseudomonas aeruginosa

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.080

7 January 2021

Correlation of T cell response and bacterial clearance in human volunteers challenged with Helicobacter pylori revealed by randomised controlled vaccination with Ty21a-based Salmonella vaccines.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.080

7 January 2021

Safety and immunogenicity of live recombinant Salmonella enterica serovar Typhi Ty21a expressing urease A and B from Helicobacter pylori in human volunteers.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.080

7 January 2021

Outer Membrane Proteins of Pseudomonas aeruginosa Serotype Strains

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.080

7 January 2021

Immunogenic efficacy of differently produced recombinant vaccines candidates against Pseudomonas aeruginosa infections

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.080

7 January 2021

Recombinant liveSalmonellaspp. for human vaccination against heterologous pathogens

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.080

7 January 2021

Regulated antigen expression in live recombinant Salmonella enterica serovar Typhimurium strongly affects colonization capabilities and specific CD4(+)-T-cell responses

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.080

7 January 2021

Salmonella typhi uses CFTR to enter intestinal epithelial cells.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.080

7 January 2021

A comparison of immunogenicity and in vivo distribution of Salmonella enterica serovar Typhi and Typhimurium live vector vaccines delivered by mucosal routes in the murine model.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.080

7 January 2021

Antibody responses in the lower respiratory tract and male urogenital tract in humans after nasal and oral vaccination with cholera toxin B subunit.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.080

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/J.VACCINE.2009.10.080

1 reference

Europe PubMed Central

24 February 2018

http://europepmc.org/abstract/MED/19887136

1 reference

Europe PubMed Central

24 February 2018

http://europepmc.org/abstract/MED/19887136

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q50052368&oldid=1794595565"